Skip to main content
SpringerLink
Log in

Value of CA 15.3 in breast cancer and comparison with CEA and TPA: A study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

The specificity and sensitivity of a tumor marker (TM) are important in establishing its potential clinical utility for a specific type of neoplasm. CA 15.3 is a TM specific for breast cancer; it is defined by two monoclonal antibodies (DF3 and 115D8), whose specificity, in disease-free follow-up patients, and sensitivity, in patients at diagnosis of first metastasis, have been evaluated in the present study and compared with those of carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA).

Serum concentrations of all three TMs were quantified in 618 individuals: 80 healthy controls, 421 patients with local breast cancer who became free of disease following locoregional treatment, and 117 patients with disseminated disease at diagnosis of metastasis. Radioimmunoassay (RIA) was the method employed, and the cut-off values obtained were 30 U/ml for CA 15.3, 5 ng/ml for CEA, and 120 U/I for TPA. The results showed CA 15.3 and CEA specificities to be analogous (95.7 and 95.5%, respectively). TPA specificity (81.9%) was lower (p<0.001). During adjuvant therapy, CA 15.3 serum levels were seen to increase, followed by a normalization of concentration after terminating therapy. On the other hand, CA 15.3 and TPA sensitivities (64.1 and 67.5%, respectively) were greater than for CEA (44.4%, p<0.01).

It is concluded that CA 15.3 is a useful TM for breast cancer, as it offers a greater sensitivity than CEA and a higher specificity than TPA. Combining CA 15.3 and CEA fails to increase CA 15.3 sensitivity, while combining CA 15.3 with TPA increases false-positives and so likewise offers no additional benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Stevens D, Mackay IR: Increased carcinoembryonic antigen in heavy cigarette smokers. Lancet ii:1238–1239, 1973

    Google Scholar 

  2. Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund C, Makela O: Comparison of a new tumor marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol 37:218–222, 1984

    PubMed  Google Scholar 

  3. Satake K, Kanazawa G, Kho I, Chung Y, Umeyama K: Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases. Am J Gastroenterol 80: 630–636, 1985

    PubMed  Google Scholar 

  4. Hoskins WJ, Burke TW, Barnhill DR: Tumor-related antigens in gynecologic cancers.In: Ghosh BC, Ghosh L (eds) Tumor Markers and Tumor-Associated Antigens. McGraw-Hill, New York 1987, pp 149–172

    Google Scholar 

  5. Novis BH, Gluck E, Thomas P, Steele GD, Zurawski VR Jr, Stewart R, Lavin PT, Zamcheck N: Serial levels of CA 19-9 and CEA in colonic cancer. J Clin Oncol 4:987–993, 1986

    PubMed  Google Scholar 

  6. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E: Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 53:278–285, 1984

    PubMed  Google Scholar 

  7. Kjorstad KE, Orjasaefer H: The prognostic significance of carcino-embryonic antigen determinations in patients with adenocarcinoma of the cervix. Gynecol Oncol 19:284–289, 1984

    PubMed  Google Scholar 

  8. Fletcher RH: Carcinoembryonic antigen. Ann Intern Med 104:66–73, 1986

    PubMed  Google Scholar 

  9. Stieber P, Diergarten K, Eiermann W, Albiez M, Fateh-Moghaadam A: CA 15.3: Evaluation and clinical value in breast carcinomas compared with CEA and TPA.In: Klapdor R (ed) New Tumour Markers and Their Monoclonal Antibodies. G Thieme Verlag, New York, 1987, pp 46–51

    Google Scholar 

  10. Delarue JC, Mouriesse H, Dubois F, Friedman S, May-Levin F: Markers in breast cancer: Does CEA add to the detection by CA 15.3? Breast Cancer Res Treat 11:273–276, 1988

    PubMed  Google Scholar 

  11. Krebs BP, Pons-Anicet D, Ramaioli A, Galland A, Rossi C, Namer M: Utilité du CA 15.3 dans le cancer du sein. Cancer Commun 2:55–64, 1988

    Google Scholar 

  12. Eskelinen M, Tikanoja S, Collan Y: Use of tumor markers CA 15.3, MCA and CEA in breast cancer diagnostics. J Tumor Markers Oncol 4:39–42, 1989

    Google Scholar 

  13. Cazin JL, Gosselin P, Boniface B, Demaille MC, Boniface M, Demaille A: Comparative values of several tumour markers: Example of untreated breast carcinoma. Br J Cancer 62:1031–1033, 1990

    PubMed  Google Scholar 

  14. Pons-Anicet D, Krebs BP, Mira R, Namer M: Value of CA 15.3 in the follow-up of breast cancer patients. Br J Cancer 55:567–569, 1987

    PubMed  Google Scholar 

  15. Vilanova C, Pastor MC, Abad-Esteve A, Rosell R, Carles J, Corominas A: Comparison of CA 15.3 and CEA in the clinical course of breast cancer [Abstract]. XVI International ISOBM Congress, Barcelona, p 134, 1988

    Google Scholar 

  16. Linares A, Rodrigo L, Garcia S, Valerdiz S, Rodriguez M, Perez R, Garcia R, Sanchez JL, Alonso JL, Arribas JM: Marcadores tumorales en el aparato digestivo: Antigeno polipeptidico histico (TPA). Jano 637:47–49, 1984

    Google Scholar 

  17. Inoue M, Inoue Y, Hiramatsu K, Ueda G: The clinical value of tissue polypeptide antigen in patients with gynecologic tumor. Cancer 55:2618–2623, 1985

    PubMed  Google Scholar 

  18. Oehr P, Adolphs HD, Altmann R: Clinical use of TPA in cancer of the urinary bladder using CEA for comparison.In: Peeters H (ed) Protides in Biological Fluids. Pergamon Press, Oxford, 1984, pp 483–486

    Google Scholar 

  19. Gion M, Mione R, Dittadi R, Fasan S, Pallini A, Bruscagnin G: Carcinoembryonic antigen ferritin and tissue polypeptide antigen in serum and tissue. Cancer 57:917–922, 1986

    PubMed  Google Scholar 

  20. Nicolini A, Capri A, Di Marco G, Giuliani L, Giordani R, Palla S: A rational postoperative follow-up with carcinoembryonic antigen, tissue polypeptide antigen, and urinary hydroxyproline in breast cancer patients. Cancer 63:2037–2046, 1989

    PubMed  Google Scholar 

  21. Barak M, Steiner M, Finkel B, Abrahamson J, Antal S, Gruener N: CA 15.3, TPA and MCA as markers for breast cancer. Eur J Cancer 26:577–580, 1990

    PubMed  Google Scholar 

  22. Tobias R, Rothwell C, Wagner J, Green A, Liu YSV: Development and evaluation of a radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115D8/DF3 [Abstract 434]. Clin Chem 31:986, 1985

    Google Scholar 

  23. Hilkens J, Hilgers J, Buijs F, Hageman PH, Schol D, Van Doornewaard G, Van Den Tweel J: Monoclonal antibodies against human milk fat globule membranes useful in carcinoma research.In: Peeters H (ed) Protides in Biological Fluids. Pergamon Press, Oxford, 1983, pp 1013–1016

    Google Scholar 

  24. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3:223–232, 1984

    PubMed  Google Scholar 

  25. Miserez AR, Günes I, Müller-Brand J, Walther E, Fridrich R, Macke H: Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA 15.3. Eur J Cancer 27:126–131, 1991

    PubMed  Google Scholar 

  26. Hayes DF, Zurawsky VR, Kufe DW: Comparison of circulating CA 15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4:1542–1550, 1986

    PubMed  Google Scholar 

  27. Colomer R, Ruibal A, Genolla J, Rubio D, Del Campo JM, Bodi R, Salvador L: Circulating CA 15.3 levels in the post surgical follow-up of breast cancer patients and in non-malignant diseases. Breast Cancer Res Treat 13:123–133, 1989

    PubMed  Google Scholar 

  28. Silver HKB, Archibald BL, Ragaz J, Coldman AJ: Relative operating characteristic analysis and group modeling for tumor markers: Comparison of CA 15.3 carcinoembryonic antigen, and mucin-like carcinomaassociated antigen in breast cancer. Cancer Res 51:1904–1909, 1991

    PubMed  Google Scholar 

  29. Vizcarra E: Marcadores tumorales CA 15.3, CEA y TPA en el cáncer de mama. Doctoral Thesis, University of Valencia, Spain, ISBN: 84-370–0610-4, 1989

  30. Viedma JA: Métodos estadísticos. Fundamentos y aplicaciones. Ed. del Castillo, Madrid, 1972

    Google Scholar 

  31. Krebs BP, Pons-Anicet D, Namer N: CA 15.3 in breast cancer: A more specific and sensitive marker than carcinoembryonic antigen (CEA).In: Klapdor R (ed) New Tumour Markers and Their Monoclonal Antibodies. G Thieme Verlag, New York, 1987, pp 60–64

    Google Scholar 

  32. Ingersleben G, Souchon R, Brand U, Fitzner R: CA 15.3 in comparison with CEA in the follow-up and therapy control of breast carcinoma. New aspects.In: Klapdor R (ed) New Tumour Markers and Their Monoclonal Antibodies. G Thieme Verlag, New York, 1987, pp 113–117

    Google Scholar 

  33. Hayes DF, Kiang DT, Korzun AH, Tondini C, Wood WC, Kufe DW: CA 15.3 and CEA spikes during chemotherapy for metastatic breast cancer [Abstract]. Proc Am Soc Clin Oncol 7:38, 1988

    Google Scholar 

  34. Colomer R, Ruibal A, Salvador L: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64: 1674–1681, 1989

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service of Hematology and Medical Oncology, University Clinic Hospital, Department of Medicine, Valencia, Spain

    E. Vizcarra, A. Lluch, F. Jarque, V. Alberola & J. García-Conde

  2. Biophysics and Medical Physics, Department of Physiology, Faculty of Medicine and Dentistry, Valencia University, Valencia, Spain

    R. Cibrián

  3. Service of Radiotherapy and Nuclear Medicine, University Clinic Hospital, Department of Medicine, Faculty of Medicine and Dentistry, Valencia University, Valencia, Spain

    V. Belloch

Authors
  1. E. Vizcarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Lluch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Cibrián
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. Jarque
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Alberola
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V. Belloch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. García-Conde
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vizcarra, E., Lluch, A., Cibrián, R. et al. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: A study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res Tr 37, 209–216 (1996). https://doi.org/10.1007/BF01806502

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806502

Key words

Search

Navigation